PharmaSecure has expanded rapidly as the pharma industry seeks to authenticate its goods amid out-of-control counterfeiting. Patients might have the most at stake in verification of medicines, with fake drugs blamed for killing thousands of people annually.
Sanofi's unit in Spain has unleashed a mobile app called CLX Dosis for calculating doses of its anticoagulant Clexane (enoxaparin).
Web search records could provide early signals of harmful drug interactions. And thanks in part to consumers' inability to resist going online to learn about their symptoms, researchers found a wealth of data to triangulate the interactions of two widely used drugs and an undesirable side effect.
Over the weekend cancer researchers and tech aces from Google and other companies teamed up to quickly blueprint a mobile game to advance research of tumor genes. It's one of the latest in a spate of missions to crowdsource tech talent and employ average citizens to take on scientific challenges.
Americans are more likely to know the names of Tom Brady's kids than the names of the last couple of scientists to win Nobel prizes in medicine. That's because our fame-infatuated culture...
After emerging from top-secret status in June, Silicon Valley Biosystems busted loose in the genomics field today with more details about its software-supported platform for enabling doctors to use genomic data in diagnosing patients.
LabLynx is elbowing in on legacy software systems with laboratory software that allows scientists to download any web app for free. Without requiring pricey IT overhead, the apps could win over labs on a budget that seek new tools to boost productivity.
Google has upped its cloud-computing game with enhancements that rival Amazon's and could give customers more opportunities to tap cloud computing.
In a move to expand, personal genomics company 23andMe has rallied investors for a $50 million Series D round of financing. The fourth-round financing came with news that the company, which had offered its personal genetic test for about $300, is cutting the price to $99.
Swiss drug giant Roche ($RHHBY) has embarked on a massive internal project to sequence cancer genes, as the company works on advancing the next wave of oncology medicines that target the triggers of tumors. And the project has involved a sizable investment in information technology and will require advances in cloud computing to take it to the next level.